2026-04-29T12:25:15Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/253632025-12-18T13:00:47Zcom_20.500.12105_2273com_20.500.12105_2202col_20.500.12105_19571

00925njm 22002777a 4500 dc Atkins, Michael B author Curiel-Lewandrowski, Clara author Fisher, David E author Swetter, Susan M author Tsao, Hensin author Aguirre-Ghiso, Julio A author Soengas, Maria S author Weeraratna, Ashani T author Flaherty, Keith T author Herlyn, Meenhard author Sosman, Jeffrey A author Tawbi, Hussein A author Pavlick, Anna C author Cassidy, Pamela B author Chandra, Sunandana author Chapman, Paul B author Daud, Adil author Eroglu, Zeynep author Ferris, Laura K author Fox, Bernard A author Gershenwald, Jeffrey E author Gibney, Geoffrey T author Grossman, Douglas author Hanks, Brent A author Hanniford, Douglas author Hernando, Eva author Jeter, Joanne M author Johnson, Douglas B author Khleif, Samir N author Kirkwood, John M author Leachman, Sancy A author Mays, Darren author Nelson, Kelly C author Sondak, Vernon K author Sullivan, Ryan J author Merlino, Glenn author Soengas, MS author 2021-05-15 Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward. Clin Cancer Res . 2021 May 15;27(10):2678-2697 https://pmc.ncbi.nlm.nih.gov/articles/PMC8127340/pdf/nihms-1659932.pdf 33414132 https://hdl.handle.net/20.500.12105/25363 TARGETED THERAPY SYSTEMIC THERAPY IMMUNOTHERAPY RECOMMENDATIONS ASSOCIATION MORTALITY SUNBURN TUMOR The State of Melanoma: Emergent Challenges and Opportunities.